Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its ...

Q4 2024 Management View CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 15:2. Implied volatility suggests the market is ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $31.52 which represents a decrease of $-1.23 or -3.76% from the prior close of $32.75. The stock opened at $31.38 and touched a ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...